New York State Common Retirement Fund
CARM

New York State Common Retirement Fund’s Carisma Therapeutics CARM Stock Holding History

New York State Common Retirement Fund’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-212
Closed -$322 – 3208
2024
Q2 		$322 Sell
212
-2,150
-91% -$3.21K ﹤0.01% 3362
2024
Q1 		$5.36K Hold
2,362
– – ﹤0.01% 3213
2023
Q4 		$6.92K Sell
2,362
-91
-4% -$271 ﹤0.01% 3205
2023
Q3 		$10.4K Sell
2,453
-8,547
-78% -$54.1K ﹤0.01% 3215
2023
Q2 		$96.5K Buy
+11,000
New +$59.9K ﹤0.01% 2870
2022
Q3 		– Sell
-90
Closed -$1K – 3292
2022
Q2 		$1K Sell
90
-6,040
-99% -$69.1K ﹤0.01% 3325
2022
Q1 		$74K Buy
6,130
+13
+0.2% +$182 ﹤0.01% 3084
2021
Q4 		$100K Sell
6,117
-6
-0.1% -$121 ﹤0.01% 3074
2021
Q3 		$97K Sell
6,123
-1,197
-16% -$57.4K ﹤0.01% 3151
2021
Q2 		$676K Buy
+7,320
New +$467K ﹤0.01% 2425
2015
Q3 		– Sell
-146
Closed -$8K – 3164
2015
Q2 		$8K Buy
+146
New +$20.6K ﹤0.01% 3297

Other funds holding CARM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TOTUOP
Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $297M AUM
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

New York State Common Retirement Fund's CARM Position: Q3 2024 in Review

New York State Common Retirement Fund sold out of Carisma Therapeutics (CARM) in Q3 2024, closing a stake of 212 shares — an estimated $322 sold.

New York State Common Retirement Fund first reported a position in CARM in Q2 2015 and held it in 11 quarters. The position peaked at $676K in Q2 2021. 37 funds tracked by Wall St. Rank hold CARM as of Q3 2024.

  • New York State Common Retirement Fund reported no remaining Carisma Therapeutics position as of Q3 2024 after selling out during the quarter.
  • New York State Common Retirement Fund sold 212 Carisma Therapeutics shares in Q3 2024, an estimated $322.
  • New York State Common Retirement Fund first reported a position in Carisma Therapeutics in Q2 2015 and held it in 11 quarters.
  • New York State Common Retirement Fund's Carisma Therapeutics position peaked at $676K in Q2 2021.
  • 37 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2024.

Based on New York State Common Retirement Fund's 13F filing for Q3 2024, filed 28 Oct 2024.